Thursday, June 10, 2021 9:30:08 AM
ProPhase Labs, Inc.
Thu, June 10, 2021, 8:30 AM
PRPH
-0.19%
ProPhase Precision Medicine, Inc. and ProPhase Global Healthcare, Inc. to Expand Opportunities in Genomics and International Testing Services
ProPhase Diagnostics, Inc. Developing New Testing Capabilities through Research and Acquisition
CEO Ted Karkus to Discuss New Initiatives at LD Micro Invitational XI Virtual Conference Today at 1:00 p.m. ET
GARDEN CITY, NY, June 10, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, today announced the formation of two wholly-owned subsidiaries, ProPhase Precision Medicine, Inc., which will focus on genomics testing technologies, and ProPhase Global Healthcare, Inc., which was recently formed to seek to expand the Company’s SARS-CoV-2 (COVID-19) testing into other countries and to pursue additional healthcare-related initiatives.
ProPhase Precision Medicine will seek to acquire existing businesses and technology, or otherwise gain access to technologies utilized to conduct whole-genome sequencing (WGS). WGS is a comprehensive method for analyzing entire genomes, including the genes and chromosomes in DNA. The data obtained from genomic testing can help to identify inherited disorders, predict disease risk, identify expected drug response, and characterize genetic mutations, including those that drive cancer progression. The costs associated with whole genome sequencing have dropped dramatically in recent years, leading to new services that can provide more detailed testing, better diagnoses, and an ability to predict the viability of therapeutic treatments.
“Whole genome sequencing is rapidly becoming a key component of the future of healthcare, with the ability to test every base in the genome,” said Ted Karkus, CEO of ProPhase Labs. “ProPhase Precision Medicine was created to explore opportunities to capture market share in the estimated multi-billion-dollar market of genomic diagnostics, offering patients the ability to understand and make informed choices about the unique genomic variants in each of us. A genomics business within the Company may be synergistic with our existing ProPhase Diagnostics operations if we are able to conduct these activities in conjunction with our current CLIA labs and leverage the extensive infrastructure already built for our other lab testing services. We intend to explore available solutions that may fit our strategy.”
“ProPhase Global Healthcare was launched with the goal of developing COVID-19 testing facilities internationally and conducting additional healthcare-related initiatives,” continued Mr. Karkus.
Karkus added, “With the onset of the global pandemic, testing demand has increased dramatically around the world, and we are well positioned to leverage our knowledge and efficiencies to capture additional share in the global testing market. As we continue to seek new laboratory acquisition targets, we are now open to opportunities that are outside the United States. This business unit is formed to pursue international opportunities in a subsidiary that will be organized in a manner best suited to international transactions.”
“Consistent with our diversification strategy, ProPhase Diagnostics is now developing antigen and antibody tests in partnerships with scientists to broaden our COVID-19 testing beyond RT-PCR testing. Additionally, we are considering the acquisition of other laboratories in the U.S. that may provide pathology, toxicology, blood, urine and oncology testing in order to expand beyond COVID-19 testing. Taken together, we are highly focused on leveraging our success in the testing business to expand into other high value testing capabilities through accretive acquisitions, licensing opportunities and R&D both here and abroad.”
Mr. Karkus added that, although the Company aspires to identify and consummate possible acquisition and expansion targets and opportunities, there can be no assurance that the Company will be able to do so.
Conference Reminder
CEO Ted Karkus will present at the LD Micro Invitational XI virtual conference taking place June 8-10, 2021. He is scheduled to host a virtual presentation during the event as follows:
2021 LD Micro Invitational XI
Date: Thursday, June 10, 2021
Time: 1:00 p.m. EDT – Track 2
Webcast: https://ldmicrojune2021.mysequire.com
A live audio webcast and archive of the event presentation will be available using the webcast link above. For more information on the LD Micro Invitational XI, or to register for the event, please visit https://ldmicrojune2021.mysequire.com.
Recent PRPH News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:04:58 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/09/2024 09:08:47 PM
- ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2024, and Highlights Significant Progress in its Strategic Initiatives. - Updated • GlobeNewswire Inc. • 05/09/2024 07:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:05:43 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/09/2024 12:00:38 PM
- ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2024, and Highlights Significant Progress in its Strategic Initiatives. • GlobeNewswire Inc. • 05/09/2024 12:00:00 PM
- PROPHASE LABS INC. TO PRESENT FIRST QUARTER 2024 FINANCIAL RESULTS ON MAY 9 • GlobeNewswire Inc. • 05/02/2024 12:00:00 PM
- ProPhase Labs to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024 • GlobeNewswire Inc. • 04/25/2024 12:00:00 PM
- ProPhase Labs Unveils Project ZenQ-AI • GlobeNewswire Inc. • 04/16/2024 12:00:00 PM
- ProPhase Labs Seeks to Transform Esophageal Cancer Detection and Management with Launch of its BE-Smart Test in H2 2024 • GlobeNewswire Inc. • 04/10/2024 12:00:00 PM
- ProPhase Labs Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/02/2024 01:00:00 AM
- ProPhase Labs Announces Financial Results for the Year Ended December 31, 2023 and Significant Progress in Its Strategic Initiatives • GlobeNewswire Inc. • 03/15/2024 12:00:00 PM
- PROPHASE LABS TO PRESENT 2023 YEAR END FINANCIAL RESULTS ON MARCH 15, 2024 • GlobeNewswire Inc. • 03/08/2024 01:00:00 PM
- ProPhase Labs Announces Significant Progress in BE-Smart Esophageal Cancer Test Development USPTO grants additional broad patents for BE-SMART • GlobeNewswire Inc. • 02/20/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:05:49 PM
- ProPhase Labs Announces Preliminary Positive Results for Dietary Supplement Equivir • GlobeNewswire Inc. • 02/14/2024 01:00:00 PM
- ProPhase Labs Ushers in New Genomics Era with Jason Karkus at the Helm of Nebula Genomics • GlobeNewswire Inc. • 01/30/2024 01:00:00 PM
- Pharmaloz Manufacturing Accelerates Expansion, Improves Pricing, Boosts Profitability and Secures New Contracts • GlobeNewswire Inc. • 01/23/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 01:05:18 PM
- ProPhase poised to ramp up growth at Pharmaloz and Nebula Genomics in 2024 • GlobeNewswire Inc. • 01/04/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:04:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 01:00:39 PM
- ProPhase Labs Announces Financial Results for the Three Months Ended September 30, 2023 • GlobeNewswire Inc. • 11/09/2023 01:00:00 PM
- ProPhase Labs to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 9, 2023 at 11:00 a.m. Eastern Time • GlobeNewswire Inc. • 11/02/2023 12:00:00 PM
- ProPhase Labs Announces Substantial Growth Expectations for Pharmaloz Manufacturing Subsidiary due to Skyrocketing Demand for Pharmaloz Output. • GlobeNewswire Inc. • 10/17/2023 12:00:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM